Loading...
•
Sep 30, 2021
Dyne Therapeutics Q3 2021 Earnings Report
Reported financial results for the third quarter of 2021 and business highlights.
Key Takeaways
Dyne Therapeutics reported its third quarter 2021 financial results, highlighting progress in advancing its co-lead programs, DYNE-251 and DYNE-101, towards clinical trials, with IND submissions anticipated in Q4 2021 and Q1 2022, respectively. The company's cash, cash equivalents, and marketable securities were $407.5 million as of September 30, 2021.
Preparing to advance Dyne’s two co-lead programs into the clinic, with the IND submission for DYNE-251 in DMD anticipated during the fourth quarter of 2021, followed by the IND submission for DYNE-101 in DM1 expected in the first quarter of 2022.
Presented new in vivo data during the World Muscle Society 2021 Virtual Congress in September 2021 demonstrating the ability of DYNE-101 in myotonic dystrophy type 1 (DM1) to target the nucleus and achieve knockdown of toxic DMPKRNA, foci reduction and correction of splicing in muscle tissues in the novel hTfR1/DMSXL mouse model.
Presented new in vivo data on October 1, 2021 during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program, showing dystrophin restoration of 90% of wild-type levels in the diaphragm and 78% in the heart with approximately 80% dystrophin-positive fibers following a single dose of FORCE in the mdx mouse model.
Held its inaugural R&D Day on October 13, 2021, highlighting preclinical data and clinical development plans for DYNE-251 in DMD and DYNE-101 in DM1.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne anticipates several milestones including IND submissions for multiple programs and participation in investor conferences.
Positive Outlook
- IND submission for DYNE-251 in DMD is planned during the fourth quarter of 2021.
- IND submission for DYNE-101 in DM1 is anticipated in the first quarter of 2022.
- IND submission for DYNE-301 in facioscapulohumeral muscular dystrophy (FSHD) is expected in the second half of 2022.
- Dyne management is scheduled to participate in fireside chats during three upcoming investor conferences.
- Cash, cash equivalents and marketable securities were $407.5 million as of September 30, 2021, which is anticipated to fund operations into the second half of 2024.